LB Pharmaceuticals Bolsters Board of Directors with Experienced Appointments

LB Pharmaceuticals has appointed William Kane and Rekha Hemrajani to its Board of Directors, bringing expertise in finance, business development, and product commercialization. The company is advancing its lead product candidate, LB-102, into Phase 3 and Phase 2 clinical trials for acute schizophrenia and bipolar depression, respectively. Kane has over three decades of biopharmaceutical leadership experience, while Hemrajani has experience in financial operations and corporate governance. They will help accelerate the company's strategic growth as it works to bring safer, more effective neuropsychiatric treatments to patients.

LB Pharmaceuticals (NASDAQ: LBRX) has bolstered its Board of Directors with strategic appointments following its recent IPO on September 10, 2025. The company has welcomed William Kane, President and CEO of Uniquity Bio, and Rekha Hemrajani, bringing significant financial and operational expertise to the board LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2]. These appointments coincide with LB Pharmaceuticals preparing to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026 LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

William Kane, with over three decades of biopharmaceutical leadership, brings extensive commercialization experience. He previously held senior roles at BioXcel Therapeutics, Allergan, and Pfizer, where he contributed to the success of multiple blockbuster products LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2]. Rekha Hemrajani, currently serving on the boards of ALX Oncology, BioAge Labs, and MaxCyte, has experience in financial operations, corporate governance, and business development. She previously held executive roles at Aravive, Arcus Biosciences, and RAPT Therapeutics LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

These appointments are crucial as LB Pharmaceuticals aims to deliver safer, more effective neuropsychiatric treatments. LB-102, a Phase 3-ready oral, small molecule, and a methylated derivative of amisulpride, has shown promising results in early clinical trials LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2]. The company's goal is to position LB-102 as the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States, potentially becoming a mainstay of psychiatric practice LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].